AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16140544
Drug: sublingual piroxicam‐FDDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual piroxicam‐FDDF 20 mg/day
Trial: 16140544
Drug: oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral azithromycin 500 mg/day
Trial: 16140544
Drug: piroxicam‐FDDF 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piroxicam‐FDDF 20 mg/day plus azithromycin 500 mg/day
Trial: 16140544
Drug: piroxicam‐FDDF 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piroxicam‐FDDF 20 mg/day
Trial: 16140544
Drug: azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azithromycin 500 mg/day
Trial: 12047415
Drug: BMS‐284756 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐284756 100 mg
Trial: 12047415
Drug: BMS‐284756 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐284756 200 mg
Trial: 12047415
Drug: BMS‐284756 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐284756 800 mg
Trial: 12047415
Drug: BMS‐284756 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐284756 1200 mg
Trial: 12047415
Drug: BMS‐284756 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐284756 (all doses)
Trial: 7603807
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (DXM)
Trial: 7603807
Drug: Neither treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither treatment (Control)
Trial: 20555371
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (CIT) 0.5 g.kg‐1 body mass
Trial: 17576847
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg flucloxacillin
Trial: 10204902
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 2% mepivacaine
Trial: 10204902
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of 2% mepivacaine
Trial: 10204902
Drug: 6 mL
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL of 2% mepivacaine
Trial: 21448197
Drug: Darbepoetin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darbepoetin (10 μg kg(‐1) subcutaneously)
Trial: 11553000
Drug: G‐CSF‐mobilized peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF‐mobilized peripheral blood stem cell (PBSC) grafts
Trial: 9692813
Drug: G‐CSF mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF mobilization
Trial: 26523993
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg daily for 104 weeks
Trial: 18490229
Drug: Preterax (perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preterax (perindopril 2 mg and indapamide 0.625 mg)
Trial: 19789415
Drug: Cilazapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (2.5 mg)
Trial: 8136096
Drug: Continue HDFP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue HDFP medication
Trial: 8136096
Drug: Withdrawn from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawn from both diuretic plus reserpine
Trial: 28301614
Drug: HP/TAZ lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP/TAZ lotion
Trial: 29328639
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid + aminocaproic acid (2 mL)
Trial: 21115926
Drug: Carboplatin (CBDCA)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CBDCA) AUC 3 and Paclitaxel (PTX) 90 mg/m² (PCb arm)
Trial: 21115926
Drug: Carboplatin (CBDCA)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CBDCA) AUC 3 plus Gemcitabine (GEM) 1000 mg/m² (GCb arm)
Trial: 10450387
Drug: Multipurpose disinfecting
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multipurpose disinfecting solution
Trial: 7480237
Drug: Azithromycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (single oral dose taken at 8 P.M. the day before surgery)
Trial: 2507125
Drug: LC9018 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC9018 with radiation therapy
Trial: 23588866
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (SEI)
Trial: 11523612
Drug: Intravenous dofetilide
RxNorm normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dofetilide
Trial: 2738584
Drug: Intradermal hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal hepatitis B vaccine
Trial: 9534677
Drug: Intramuscular hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hepatitis B vaccine
Trial: 2399180
Drug: Diazepam (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.6 mg/kg)
Trial: 11701431
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg testosterone enanthate
Trial: 11701431
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg testosterone enanthate
Trial: 11701431
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg testosterone enanthate
Trial: 18639360
Drug: Dose Matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Matched Therapeutic Exercises (DMTE)
Trial: 11739462
Drug: E2 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 supplementation (1 mg micronized 17 beta‐E2 orally twice daily for 6‐23 days)
Trial: 19554657
Drug: Sodium phosphate
RxNorm normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium phosphate plus 240 mg of tablet simethicone
Trial: 15586301
Drug: Mepivacaine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine 4% with 0.1 mg of morphine
Trial: 2979673
Drug: Pirenzepine 100
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 100 mg
Trial: 2979673
Drug: Propantheline 15
RxNorm normalized name: propantheline 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propantheline 15 mg
Trial: 2979673
Drug: Propantheline 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propantheline 45 mg
Trial: 23686894
Drug: Vaccinium arctostaphylos
RxNorm normalized name: Arctostaphylos tomentosa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinium arctostaphylos fruit hydroalcoholic extract (350 mg capsule every 8 hours for 2 months)
Trial: 20019589
Drug: Clopidogrel Leti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel Leti 75 mg
Trial: 20019589
Drug: Clopidogrel Sanofi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel Sanofi (Plavix) 75 mg
Trial: 11875324
Drug: Amiloride 2.5
RxNorm normalized name: amiloride 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 2.5 + Hydrochlorothiazide 5 mg
Trial: 6573315
Drug: Cefotetan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan 0.5 g
Trial: 6573315
Drug: Cefotetan 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan 1.0 g
Trial: 695661
Drug: Prophylactic gestagen
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic gestagen therapy in the immediate post-ovulatory phase
Trial: 23482914
Drug: 100 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 kVp setting and 370 mgI/mL contrast medium
Trial: 23482914
Drug: 100 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 kVp setting and 300 mgI/mL contrast medium
Trial: 23482914
Drug: 120 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 kVp setting and 370 mgI/mL contrast medium
Trial: 19153029
Drug: Yunnan Baiyao
RxNorm normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yunnan Baiyao capsules
Trial: 8006280
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day of aspirin for 8 days
Trial: 8006280
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not treated with aspirin)
Trial: 8006280
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose aspirin therapy during pacing
Trial: 25664701
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded implants (test group)
Trial: 25664701
Drug: Delayed loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loaded implants (control group)
Trial: 21862415
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate (1.4 mg/m²) administered on days 1 and 8 of a 21-day cycle.
Trial: 21862415
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate (1.4 mg/m²) administered on days 1, 8, and 15 of a 28-day cycle.
Trial: 14646651
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 8 mg IV dexamethasone 1 hour before the operation
Trial: 14646651
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 8 mg IV dexamethasone at the beginning of the operation
Trial: 14646651
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 8 mg IV dexamethasone 1 hour before the operation, and 24 and 48 hours after the operation
Trial: 14646651
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 8 mg IV dexamethasone at the beginning of the operation, and 24 and 48 hours after the operation
Trial: 14646651
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 8 mg IV dexamethasone immediately after the operation, and 24 and 48 hours after the operation
Trial: 14646651
Drug: Control, no
RxNorm normalized name: Ascensia Autodisc Control, Normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control, no dexamethasone administration before or after the operation
Trial: 1955549
Drug: Control (natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (natural intercourse after clomiphene treatment)
Trial: 24401721
Drug: Coupled plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coupled plasma filtration adsorption (CPFA) with dose >0.18 L/kg/day
Trial: 17350481
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg/day, titrated to 100 mg TDS)
Trial: 15732035
Drug: Combination mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination mycophenolate mofetil and prednisone (MMF-P)
Trial: 10561297
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m² IV over 3 hours for eight cycles (24 weeks)
Trial: 10561297
Drug: CMFP combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMFP combination chemotherapy (cyclophosphamide 100 mg/m²/d orally on days 1 to 14, methotrexate 40 mg/m² IV on days 1 and 8, fluorouracil 600 mg/m² IV on days 1 and 8, and prednisone 40 mg/m²/d orally on days 1 to 14) for six cycles (24 weeks)
Trial: 8702043
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) antimalarial treatment and chemoprophylaxis
Trial: 8702043
Drug: Mefloquine (MQ)
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefloquine (MQ) antimalarial treatment and chemoprophylaxis
Trial: 8702043
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) and Mefloquine (MQ) antimalarial treatment and chemoprophylaxis
Trial: 31399071
Drug: Community mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community mental health treatment and HIV counseling and testing
Trial: 28114648
Drug: Provider intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Provider intervention (electronic delivery of patient-specific osteoarthritis treatment recommendations)
Trial: 23340519
Drug: 8-week MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-week MPH treatment (follow-up for 7 patients)
Trial: 10626860
Drug: 0.2% GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% GTN ointment
Trial: 11339416
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT2) for 2 weeks
Trial: 11339416
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT3) for 3 weeks
Trial: 11072531
Drug: ISDN-SR 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN-SR 480 mg a day (4-times-daily)
Trial: 7659429
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments (including anxiolytics)
Trial: 1657528
Drug: Lidoflazine (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidoflazine (calcium entry blocker) administered intravenously after restoration of spontaneous circulation
Trial: 30365356
Drug: High-dose iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose iron sucrose (400 mg monthly)
Trial: 29991700
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (MT)
Trial: 27483130
Drug: Guanfacine immediate-release
RxNorm normalized name: guanfacine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine immediate-release (GUAN-IR) 1-3 mg/day
Trial: 15848906
Drug: Reduced overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced overall treatment time (OTT) of radiotherapy (9.5, 6.5, and 5.5 weeks)
Trial: 1683340
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg zotepine
Trial: 1683340
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg zotepine
Trial: 1683340
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg zotepine
Trial: 23053769
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral therapy (COT) including pyrimethamine, sulfadiazine, folinic acid and prednisone
Trial: 23053769
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral therapy (COT)
Trial: 21770716
Drug: DPSGC 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPSGC 100 mg
Trial: 19487635
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin infusion at 1.0 and 2.0 units/h
Trial: 7977180
Drug: Group condition
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group condition (G) - received self-help manuals, watched a 20-day televised series, participated in six sessions emphasizing quitting techniques and social support, and monthly peer-led support groups with incentives.
Trial: 7977180
Drug: Nongroup condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nongroup condition (NG) - received self-help manuals and watched a 20-day televised series, but no further treatment after the initial phase.
Trial: 20819898
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation at 0 mg/kg per day (placebo)
Trial: 20819898
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation at 1 mg/kg per day
Trial: 20819898
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation at 2 mg/kg per day
Trial: 10674681
Drug: Primaquine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (30 mg a day for 14 days)
Trial: 10674681
Drug: Artesunate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (200 mg once a day for 3 days) plus primaquine (30 mg a day for 14 days)
Trial: 2404389
Drug: Prolonged infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged infusion of intravenous heparin for greater than or equal to 72 hours (group 2)
Trial: 29676197
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of strontium ranelate
Trial: 21036891
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg three times per day)
Trial: 12066084
Drug: Supracervical Foley
RxNorm normalized name: CATHETER,FOLEY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supracervical Foley catheter and 100 microg oral doses of misoprostol
Trial: 12066084
Drug: Serial 100‐microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial 100‐microg oral doses of misoprostol
Trial: 9831997
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride (n = 77) in flexible doses up to 200 mg
Trial: 7521313
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 150 mg/day
Trial: 7521313
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 600 mg/day
Trial: 7521313
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 900 mg/day
Trial: 31630035
Drug: Celecoxib (CBX)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib (CBX) adjunctive treatment
Trial: 16847150
Drug: hsCRP >3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP >3 mg/L
Trial: 27328699
Drug: hsCRP <1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP <1 mg/L
Trial: 24259978
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg AMT before bedtime
Trial: 24259978
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Pantoprazole once daily for 4 weeks
Trial: 22309474
Drug: 10-week psychosocial
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-week psychosocial treatment involving parent management training for ADHD and family-based cognitive-behavioral therapy for anxiety.
Trial: 22309474
Drug: 10-week psychosocial
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-week psychosocial treatment
Trial: 31764732
Drug: Acetaminophen (Control)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (Control)
Trial: 7884951
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of ibuprofen
Trial: 7884951
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of ibuprofen
Trial: 7884951
Drug: 12 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/kg of acetaminophen
Trial: 6453432
Drug: Clearfil Bonding
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clearfil Bonding Agent
Trial: 30559054
Drug: Octenilin® wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octenilin® wound gel
Trial: 28132813
Drug: Ketanserin (5-HT2AR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (5-HT2AR antagonist)
Trial: 25181938
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy and progressive muscle relaxation training plus routine nursing care
Trial: 21384392
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss supplement (Curva™) in conjunction with low-level laser treatments